



For more information please ask one of
the research team or visit:

www.lasertrial.co.uk

Or, contact us:

info@lasertrial.co.uk
07730619850



www.lasertrial.co.uk

LASER Patient Information Leaflet | v1.0 | 5/Feb/2014

Portsmouth Hospitals NHS Trust



The LASER Trial
A clinical trial for patients with
poorly-controlled, severe,
allergic asthma

trial.The LASER Trial

Laminar Airflow in Severe Asthma for Exacerbation Reduction

The LASER trial will assess whether the addition of Temperature-controlled Laminar Airflow (TLA) treatment to standard asthma therapy in patients with poorly-controlled, severe, allergic asthma will help to reduce the frequency of asthma attacks ('exacerbations').

Temperature controlled Laminar Airflow is delivered by a treatment device called the Airsonett® device which is installed in the participant's bedroom and used overnight whilst they sleep.



222 participants will be included in the trial. 111 will receive an active TLA treatment device and 111 will receive a placebo TLA device. Neither the trial team nor the participant will know which device they have during their 12 month

Am I eligible to take part?

We are looking for patients with allergic asthma that is poorly controlled despite high intensity treatments.

If you have asthma that is made worse by indoor allergens (such as cats / dogs / dusts / moulds) and you require daily treatment with steroid inhalers or steroid tablets and you still get symptoms despite this with breathlessness, wheeze, night time waking and additional reliever inhaler use then you might be eligible to take part.

What does taking part involve?

Taking part in the clinical trial involves 12 months of treatment with Temperature-controlled Laminar Airflow (TLA).

You will be asked to visit the hospital 6 times, twice at the start of the trial to check that you are suitable and to perform baseline tests and then a further 4 times during the 12 months of TLA treatment to see what affect the treatment is having on your asthma.

You will be asked to perform breathing tests and complete questionnaires at each of the visits and there is a blood test at the start of the trial.



The Airsonett® Device

The treatment device being tested is called the 'Airsonett®' device.

The device is manufactured in Sweden.

The Airsonett® device works by dramatically reducing the number of allergy particles that are inhaled overnight whilst a patient is asleep.

Airsonett® creates a zone of filtered air in the breathing zone and breaks the allergen rich flow of air caused by body convection. This allows the patient's lungs to 'rest' overnight and recover from the inflammation caused by inhaling allergy particles.



Airsonett® Technical Specifications:

Weight: 25kg

Height: 94-139cm (depending on type of bed)

Base unit - Length: 54cm Width: 34cm

Energy Consumption: Equivalent to 1 standard 60W light